Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A double-blind, placebo-controlled trial of a slow-release preparation of 5-amino-salicylic acid (Pentasa) has been performed in 40 patients with active Crohn's disease. Over a 6-week period, Pentasa (1.5 g daily) was no different to the dummy tablet in terms of clinical activity (Harvey-Bradshaw Index) or laboratory indicators of inflammation. No serious adverse reactions occurred.

Original publication

DOI

10.1159/000200228

Type

Journal article

Journal

Digestion

Publication Date

1990

Volume

45

Pages

88 - 92

Keywords

Adult, Aminosalicylic Acids, Crohn Disease, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Male, Mesalamine, Randomized Controlled Trials as Topic, Time Factors